CADL PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

CADL ▲ +13.01% at T+20d

NEUTRAL call ✓ call won +13.01% · α vs SPY +7.37% · entry $7.53 → $8.51

Next anchor: T+60d in 7w

Last close $8.50 (close Jun 8) · +12.88% from $7.53 entry

Entry anchored
May 1, 03:59 PM ET
via Databento tick

T+1d

+1.86%

call +1.86% · α +1.06%

$7.67

settled 5w ago

T+5d

+17.53%

call +17.53% · α +14.59%

$8.85

settled 4w ago

T+20d

+13.01%

call +13.01% · α +7.37%

$8.51

settled 8d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Candel Therapeutics announced a conference call on May 15, 2026, to discuss extended follow-up data from the Phase 3 trial of CAN-2409 in prostate cancer, following an oral plenary presentation at AUA 2026. The call features key opinion leaders, but no new data or regulatory decision is disclosed in this press release, making it a routine event update.

Actionable Insight

Monitor the May 15 call for extended follow-up data from the Phase 3 prostate cancer trial; positive efficacy or safety signals could drive significant upside for CADL. The stock may trade on anticipation ahead of the AUA presentation.

Key Facts

Conference call scheduled for May 15, 2026, at 1:00 PM ET to discuss Phase 3 extended follow-up data for CAN-2409 in intermediate- to high-risk localized prostate cancer.
Data will be presented as an oral plenary at the AUA 2026 Annual Meeting.
Call will feature insights from leading prostate cancer specialists including Drs. Shore, Tward, and George.
CAN-2409 has FDA Fast Track and Regenerative Medicine Advanced Therapy Designations for prostate cancer.
No new clinical data, regulatory updates, or financial figures are provided in this press release.

Financial Impact

No financial impact disclosed; event is a data presentation update.

Risk Factors

Extended follow-up data may not show statistically significant improvement over placebo.
Regulatory path for CAN-2409 remains uncertain pending full data readout.
Clinical-stage biotech carries high risk of trial failure or delays.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

87% bullish (15 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3286676

9 reports for CADL

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+1▲ +4.51%Jun 2, 2026

Filters

Reports for CADL — sortable, filterable
	Type				Now
Jun 2, 2026 7d ago	Press Release BULLISH ★ 8/10	$8.42 $8.80	▲ +4.51%	▲ +5.21%	$8.50 (+0.95%)
May 15, 2026 25d ago	Press Release BULLISH ★ 8/10	$7.90 $7.66	▼ −3.04%	▼ −2.39%	$8.50 (+7.59%)
May 14, 2026 26d ago	8-K NEUTRAL ★ 4/10	$8.91 $8.77	▼ −1.57%	▼ −0.34%	$8.50 (−4.60%)
May 14, 2026 26d ago	Press Release NEUTRAL ★ 5/10	$8.91 $8.77	▼ −1.57%	▼ −0.34%	$8.50 (−4.60%)
May 4, 2026 5w ago	Press Release NEUTRAL ★ 3/10	$7.53 $7.67	▲ +1.86%	▲ +1.06%	$8.50 (+12.88%)
Apr 29, 2026 5w ago	Press Release NEUTRAL ★ 3/10	$6.18 $6.18	· 0.00%	▼ −1.02%	$8.50 (+37.54%)
Mar 17, 2026 12w ago	Press Release BULLISH ★ 8/10	$5.17 $5.04	▼ −2.51%	▼ −1.12%	$8.50 (+64.41%)
Mar 12, 2026 12w ago	8-K NEUTRAL ★ 4/10	$4.98 $4.67	▼ −6.22%	▼ −5.63%	$8.50 (+70.68%)
Mar 12, 2026 12w ago	Press Release MIXED ★ 6/10	$4.98 $4.67	▼ −6.22%	▼ −5.63%	$8.50 (+70.68%)

US Market Status

Market Closed — Opens in 7h 11m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access